Latest in Cardiology from ACC.org

• ASSET-IT: Early Tirofiban Increases Functional Outcomes For Noncardioembolic Stroke
  Early tirofiban significantly improved the likelihood of disability-free and functionally independent outcomes in patients with acute ischemic noncardioembolic stroke who receive thrombolysis within 4.5 hours after onset, according to results from the phase 3 ASSET-IT trial, published July 3 in NEJM.
• Federal Government Shuts Down as Telehealth Flexibilities Lapse
  The federal government shut down on Oct. 1 as lawmakers failed to reach a funding agreement. According to contingency plans from the Centers for Medicare and Medicaid Services (CMS), operations such as claims processing for Medicare, Medicaid and the Children's Health Insurance Program will continue.
• Eagle’s Eye View: Oral Semaglutide for Weight Loss; Anticoagulants for PAH; The ECDP on TR Evaluation and Management
  In this week’s View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH).
• Nicole Bhave, MD, FACC, Named ACC Annual Scientific Session Vice Chair
  The ACC has named Nicole Martin Bhave, MD, FACC, as the next Annual Scientific Session vice chair for ACC.27 and ACC.28. Her term will be followed by a two-year term as chair for ACC.29 and ACC.30.
• Nearly Everyone Has One or More CV Risk Factors Before a CVD Event
  Almost all individuals (99%) who experienced a cardiovascular disease event were exposed to one or more nonoptimal traditional risk factor, challenging the belief that cardiovascular disease often strikes people without warning, according to a large study published Sept. 29 in JACC.